Preoperative irradiation, lymphadenectomy and 125iodine implant for patients with localized prostatic carcinoma: a correlation of implant dosimetry with clinical results.
The 30 patients with clinically and surgically localized prostatic carcinoma who were selected for treatment by a short course of preoperative irradiation (1,050 rad), pelvic lymphadenectomy and 125iodine implant have been followed for 1 to 4 years. Perioperative morbidity (10 per cent), postimplant impotence (11 per cent), lymphedema (17 per cent), tumor recurrence (4 per cent) and distant metastasis (4 per cent) have been minimal to date. However, urinary irritative symptoms, which usually subsided in 6 to 9 months, occurred in half of the patients and correlated with implant volume. Total dose and total dose per unit of implanted activity were calculated. Of the various implant parameters evaluated implant dose homogeneity has corrrelated with the rate of tumor regression.
D001918:Brachytherapy / Q000009:adverse effects; D007172:Erectile Dysfunction / Q000209:etiology; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008197:Lymph Node Excision; D008297:Male; D009364:Neoplasm Recurrence, Local; D009366:Neoplasm Seeding; D010388:Pelvis; D011300:Preoperative Care; D011471:Prostatic Neoplasms / Q000628:therapy*; D011879:Radiotherapy Dosage; D014555:Urination Disorders / Q000209:etiology
D007457:Iodine Radioisotopes